Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife Inc. director Daniel S. Glaser filed an initial ownership report showing a direct holding of 1,305 shares of MetLife common stock. This Form 3 filing establishes his starting equity position as a company insider, which will serve as the baseline for any future reported transactions.
MetLife, Inc. disclosed that on February 26, 2026 it issued $1,000,000,000 aggregate principal amount of 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056. The debentures are issued under a 2005 indenture with The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented on February 26, 2026.
The debentures were offered and sold under a shelf registration statement on Form S-3 and a February 24, 2026 prospectus supplement. MetLife entered into an underwriting agreement and a pricing agreement with major underwriters including Barclays Capital, BofA Securities, Citigroup, Goldman Sachs, Morgan Stanley and Wells Fargo Securities.
MetLife, Inc. is offering $1,000,000,000 of 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due March 15, 2056. The Debentures pay 5.850% through the Initial Interest Reset Date of March 15, 2036, then reset every five years to the Five-Year Treasury Rate plus 1.817%. Interest is payable semi-annually on March 15 and September 15, beginning September 15, 2026. MetLife may defer interest for Optional Deferral Periods up to five years, and the Debentures are unsecured and subordinated to MetLife’s senior indebtedness and structurally subordinated to subsidiary liabilities. Net proceeds are expected to be approximately $987.8 million for general corporate purposes, with settlement expected on or about February 26, 2026.
MetLife, Inc. reported that its Board of Directors increased its size from eleven to thirteen members and elected Daniel S. Glaser and Michelle R. Seitz as new directors effective February 24, 2026. Both were also appointed to multiple key Board committees and were determined to be independent directors.
Each new director will receive MetLife’s standard non-management director compensation, which currently consists of a $355,000 annual retainer, with $205,000 paid in common stock and $150,000 paid in cash. Retainers are pro-rated for partial-year service, with the first of four annual installments earned at the beginning of service.
MetLife, Inc. is offering fixed-to-fixed reset rate subordinated debentures due 2056 via a preliminary prospectus supplement dated February 24, 2026, supplementing the May 16, 2025 prospectus. The securities are unsecured, subordinated obligations that rank pari passu with the 2055 SDs and junior to MetLife’s senior indebtedness and subsidiary liabilities. Interest is payable semi-annually and initially fixed through the Initial Interest Reset Date, thereafter resetting each five years to the Five-Year Treasury Rate plus a spread. MetLife may defer interest for up to five consecutive years per Optional Deferral and may redeem the Debentures under specified conditions, including Tax, Rating Agency or Regulatory Capital Events. The Debentures will be issued in book-entry form and are not listed on any exchange.
MetLife, Inc.’s board is reporting beneficial ownership of 105,374,380 shares, or 16.2% of the company’s common stock, through the MetLife Policyholder Trust. This ownership reflects shares held in the name of Wilmington Trust Company as trustee for eligible policyholders.
The trust was originally issued 494,466,664 shares on April 7, 2000 under MetLife’s demutualization plan, but transactions by beneficiaries, a 2008 split-off, withdrawals, and escheatment have reduced the holdings to the current level as of February 12, 2026. The board is deemed to share voting power because the trustee generally follows board voting recommendations, except on defined “Beneficiary Consent Matters,” where votes reflect beneficiary instructions.
Beneficiaries hold fractional trust interests rather than legal title to the shares, but they are entitled to dividends and proceeds from sales of their allocated shares. Between October 31, 2025 and the current report, beneficiary-related activity decreased the trust’s holdings from 106,549,803 to 105,374,380 shares.
MetLife, Inc. presents its annual report describing how it plans to grow under its four-year New Frontier strategy, focusing on group benefits, retirement platforms, asset management and international markets. The company reorganized into six segments and elevated MetLife Investment Management (MIM) to a reportable segment.
MetLife completed the acquisition of global asset manager PineBridge Investments to add scale and broaden investment products and distribution for institutional clients. The filing also details extensive U.S. and international insurance, capital and solvency regulation, climate and cybersecurity oversight, and data privacy rules that shape MetLife’s capital, product, and risk management decisions worldwide.
MetLife, Inc. declared a series of preferred stock dividends for first quarter 2026. The company approved a semi-annual dividend of $29.375 per share on its 5.875% fixed-to-floating rate preferred stock, Series D, and quarterly dividends of $351.5625 per share on Series E and $296.875 per share on Series F, with holders of the related depositary shares receiving $0.3515625 and $0.296875 per share, respectively. MetLife also declared a quarterly dividend of $0.31501229 per share on its floating rate preferred stock, Series A, subject to final confirmation that it has met specified financial tests. All these dividends are payable on March 16, 2026, to shareholders of record as of February 27, 2026.
MetLife, Inc. filed a Form 13F reporting holdings as a 13F Combination Report that lists 6 Form 13F information table entries with a total reported value of $12,153,950.
The filing is submitted on behalf of MetLife investment managers and is signed by John McCallion, EVP, CFO and Head of MetLife Investment Management.
MetLife, Inc. furnished its quarterly and full-year 2025 earnings materials and provided an updated multi-year outlook. The company reported $3.6 billion of cash and liquid assets at its holding companies as of December 31, 2025, which is within its $3.0 billion to $4.0 billion target range, and plans to maintain this target in 2026.
MetLife states it returned approximately $4.4 billion to shareholders in 2025 and remains on track to generate about $25.0 billion of free cash flow over 2025–2029. Assuming a 10-year U.S. Treasury rate of 4.40% at December 31, 2026, S&P 500 annual returns of 5% and private equity returns of 9% in 2026, it estimates $1.6 billion of pre-tax variable investment income for 2026 and expects its two-year average free cash flow to adjusted earnings ratio to stay at 65%–75%. The company is maintaining near-term annual targets for adjusted return on equity of 15%–17%, double-digit adjusted earnings per share growth, and direct expense ratio targets of 12.1% for 2026 and 11.3% in 2029, while indicating it does not expect material liquidity deficiencies or covenant issues.
MetLife, Inc. furnished its quarterly and full-year 2025 earnings materials and provided an updated multi-year outlook. The company reported $3.6 billion of cash and liquid assets at its holding companies as of December 31, 2025, which is within its $3.0 billion to $4.0 billion target range, and plans to maintain this target in 2026.
MetLife states it returned approximately $4.4 billion to shareholders in 2025 and remains on track to generate about $25.0 billion of free cash flow over 2025–2029. Assuming a 10-year U.S. Treasury rate of 4.40% at December 31, 2026, S&P 500 annual returns of 5% and private equity returns of 9% in 2026, it estimates $1.6 billion of pre-tax variable investment income for 2026 and expects its two-year average free cash flow to adjusted earnings ratio to stay at 65%–75%. The company is maintaining near-term annual targets for adjusted return on equity of 15%–17%, double-digit adjusted earnings per share growth, and direct expense ratio targets of 12.1% for 2026 and 11.3% in 2029, while indicating it does not expect material liquidity deficiencies or covenant issues.